StockWatch
·
Q1 FY-2027 RESULTS · MANIPALHOS

Manipal Hospitals Q1FY27: consolidated PAT down 4% YoY despite 38% revenue growth

PAT -4.2% YoY · revenue +38.1% · margins compressing

Q1 FY27 resultsMANIPALHOSManipal Health Enterprises Ltd20 Aug 2026 · 3 min read
Revenue

₹3,090.63 Cr

+38.1% YoY

PAT (consolidated)

₹243.43 Cr

-4.2% YoY

Net margin

7.69%

EPS

₹1.96

Manipal Health Enterprises (Manipal Hospitals) reported consolidated revenue of ₹3,090.63 Cr for the quarter ended June 30, 2026, up 38.1% YoY (+7.2% QoQ), but consolidated net profit fell to ₹243.43 Cr, down 4.2% YoY (owners' share ₹231.65 Cr, down 7.5% YoY; EPS ₹1.96 vs ₹2.17 a year ago, -9.7%). Adjusting for the near-identical exceptional charge both years (₹15.47 Cr now vs ₹18.40 Cr YoY), adjusted PAT still fell roughly 4.6% YoY — this is not a one-off-driven decline, it is a genuine margin story. Standalone (parent-only) told the same story: revenue up 28.2% YoY to ₹1,048.30 Cr, PAT down 8.3% YoY to ₹115.53 Cr.

The scoreboard

Q1 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹3,090.63 Cr
Expenses₹2,834.54 Cr
PAT₹243.43 Cr+30.5%-4.2%
Net margin7.69%
EPS₹1.96

No year-ago quarter on record — YoY cells may be blank.

The gap between strong topline growth and shrinking profit sits almost entirely on two lines: finance costs, which surged 123% YoY to ₹293.27 Cr (from ₹131.61 Cr), and depreciation, up 33% YoY to ₹187.25 Cr (from ₹140.63 Cr) — both consistent with debt-funded hospital acquisitions (notably the Sahyadri Hospitals controlling stake bought in October 2025) now sitting on the consolidated balance sheet for a full quarter versus none in the year-ago base. Consolidated net profit margin compressed to 7.7% from 11.1% a year ago, though it did improve sequentially from 6.4% in the March 2026 quarter, and operating profit margin (pre-exceptional PBT/total income) similarly moved to 10.4% from 15.9% YoY but up from 8.7% QoQ — sequential trends are healthier than the YoY trend, which is the one that matters for the verdict.

We have no prior guidance or concall commentary on record for this company, and a web search turned up no analyst consensus estimates for this print either — this is the company's first quarterly result as a listed entity, having completed its ₹8,000 Cr fresh-issue IPO at ₹590/share on August 5, 2026, after this quarter had already closed, so the deleveraging benefit from IPO proceeds is not yet visible in these numbers. Two corporate actions from this reporting window are notable but not yet reflected in the P&L: the company signed a Business Transfer Agreement to acquire Kinder Women's Hospital, Bengaluru, for ₹130 Cr (subsequent to quarter-end, disclosed Aug 17-18, 2026), continuing the inorganic-growth pattern that is already driving the elevated finance-cost and depreciation base.

  • W1

    Whether Q2 FY27 finance costs decline as ₹8,000 Cr IPO proceeds (raised Aug 5, 2026) are deployed to cut debt — this quarter's consolidated finance cost was ₹293.27 Cr

  • W2

    Whether NPM (7.7% this quarter vs 11.1% a year ago, 6.4% in Mar-26 quarter) continues its sequential recovery as acquisition-integration costs normalize

  • W3

    Revenue/EBITDA contribution from the ₹130 Cr Kinder Women's Hospital acquisition (BTA signed post quarter-end) once it consolidates

Informational and educational content only. Not investment advice.